Compare Prospect Capital Corporation (PSEC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Prospect Capital Corporation trades at $1.58 (market cap $848.77M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 8.7× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 26.42% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PSEC | SYRE | |
|---|---|---|
Market Cap | $848.77M | $7.35B |
Volume | 7,084,485 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $3.05 | $108.92 |
52-Week Low | $1.60 | $22.18 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $2.67B | $6.35B |
Dividend Yield | 26.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.67, down 3.47% today, with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but negative revenue and net income in 2025. Recent earnings have consistently beaten expectations, though the company faces significant financial volatility with revenue swinging from $635M in 2022 to -$407M in 2025. Dividend distributions continue at $0.04 monthly, providing income appeal despite operational challenges.
The outlook remains cautious with analyst consensus leaning Hold (55%) amid financial instability. Key risks include persistent revenue volatility and negative cash flow. Upside potential exists from consistent earnings beats and deep valuation discounts, but investors should weigh income benefits against fundamental deterioration and bearish technical momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
